Lupus & antiphospholipid syndrome
Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial
Authors' conclusion
Compared with placebo, anifrolumab treatment significantly reduced urinary biomarkers of renal histologic activity in patients with LN
Study context
- Population
- Patients with lupus nephritis (LN) receiving standard therapy in the phase 2 TULIP-LN trial; urine samples at weeks 0, 12 and 48 analysed for 197 proteins
- Participants
- 35 / 42 / 35
- Comparison
- Anifrolumab plus standard therapy vs placebo plus standard therapy
- Basic regimenn = 35
- Intensified regimenn = 42
- Placebon = 35reference
- Primary endpoint
- Impact of anifrolumab vs placebo on prespecified urinary biomarkers linked to histologic activity
Methodological detailsphase 2, proteomic analysis, placebo-controlled
- Phase 2
- Proteomic analysis
- Placebo-controlled
Primary result
As reported in the abstract
Urinary CD163 and monocyte chemoattractant protein 1 · week 12
- Anifrolumab significantly reduced urinary CD163 and monocyte chemoattractant protein 1 expression vs placebo, including in proteinuric nonresponders across all regimens
Further findings
Urinary biomarker levels · week 48
- Biomarker levels declined in all groups, indicating standard therapy alone can eventually suppress intrarenal inflammation but with slower kinetics
Proteomic inflammatory signature
- Anifrolumab superior to placebo in reducing the proteomic inflammatory signature, regardless of responder status
Original publication
Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial. Arthritis Rheumatol. Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →